| Date | Title | | | 03/08/10 | Celldex Therapeutics to Present at the Cowen & Company 30th
Annual Health Care Conference| NEEDHAM, Mass., Mar 08, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony
S. Marucci, President and Chief Executive Officer of Celldex
Therapeutics, Inc., will present at the 30th Annual Cowen &
Company Health Care Conference at the Boston Marriott Copley Place on
Wednesday, March 10, 2010 at 11:00 a.m. Eastern Time.
A live webcast of the presentation will be available on the
"Presentations" page of the "In... |
|  | | 03/04/10 | Celldex Reports Fourth Quarter and Fiscal 2009 Financial Results| - Management to Host Conference Call to Discuss Results and Provide 2010 Outlook Today, Thursday, March 4, at 9:00 a.m. Eastern Time -NEEDHAM, Mass., Mar 04, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial
results for the fourth quarter and year ended December 31, 2009. Celldex
reported a net loss of $13.5 million, or $0.43 per share, for the fourth
quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per
shar... |
| | | 02/25/10 | Celldex Therapeutics to Report Fourth-Quarter and Fiscal 2009
Financial Results and Provide Outlook for 2010 on March 4, 2010| - Conference Call to Follow at 9:00 am -NEEDHAM, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) will release its fourth
quarter and fiscal 2009 financial results before U.S. financial markets
open on Thursday, March 4, 2010. Celldex executives will host a
conference call at 9:00 A.M. Eastern Time on the same day to provide a
year-end summary for 2009 and an update on anticipated research and
development and business object... |
| | | 02/16/10 | Celldex Receives $3 Million Sublicense Income Payment from TopoTarget| NEEDHAM, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that it has
received a sublicense income payment of $3 million from TopoTarget A/S
(NASDAQ-OMX: TOPO.CO) as a result of the recent co-development and
commercialization agreement between TopoTarget and Spectrum
Pharmaceuticals, Inc. (NASDAQ: SPPI) for Belinostat, a novel histone
deacetylase (HDAC) inhibitor for the treatment of cancer. In this
t... |
| |
|
